Latest News

Xention and Servier Announce a €120m Cardiovascular Collaboration.

Xention and Servier announce a €120M cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation. October 2nd, 2013, Cambridge, UK and Suresnes, France– Xention Ltd., a portfolio company of Seroba Kernel based in Cambridge and specialising in the discovery and development of ion channel-modulating...


Crescent Diagnostics appoints Barry Clare as Chairman.

Dublin, Ireland. 9 September 2013. … Crescent Diagnostics Ltd (“Crescent”), a Seroba Kernel portfolio company and a developer of novel tests for predicting osteoporotic fracture risk, is pleased to announce the appointment of Barry Clare as Chairman. Barry was previously a main board director at The Boots Company PLC, and is currently CEO and Chairman of Healthcare Brands...


Apica Cardiovascular has received CE Mark Approval

Dublin, September 4th, 2013 – Galway based, Apica Cardiovascular, has received CE Mark Approval for its platform Access, Stabilisation, and Closure (ASC™) system that allows for the delivery of aortic and mitral valves through the chest wall and apex of the beating heart. The ASC system is a breakthrough enabling platform technology that can be used by surgeons, in...


< back to home page